Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 1/2

CMTS0515-auWMT for Radiation Enteritis

NCT07331688 · tracked via the Priya Life Science China tracker
Phase
Phase 1/2
Started
2025-12-08
Last updated
2026-01-12

Condition(s) studied

Radiation Enteritis

Investigational drug(s) / intervention(s)

CMTS0515-augmented washed microbiota transplantationWashed Microbiota Transplantation

CMTS0515-augmented washed microbiota transplantation: Lyophilized CMTS0515 is added to washed microbiota suspension and administered via mid-gut or colonic transendoscopic enteral tube.

Washed Microbiota Transplantation: Washed microbiota suspension delivered through mid-gut and lower-gut transendoscopic enteral tube.

Study summary

This is a randomized controlled trial to explore the exploring the non-inferiority of CMTS0515-augmented WMT compared to WMT.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Histopathologically confirmed diagnosis of abdominal or pelvic cancer; 2. Completion of at least one entire course of radiation therapy; 3. Age ≥18 years at the time of cancer diagnosis. Exclusion Criteria: 1. Absence of intestinal symptoms or transient intestinal symptoms; 2. Radiation treatment involving areas outside the abdomen and pelvis; 3. Diagnosis of antibiotic-associated diarrhea or use of antibiotics within four weeks before enrollment; 4. Presence of intestinal comorbidities, including inflammatory bowel disease or pseudomembranous colitis; 5. Presence of severe conditions rendering the patient unsuitable for inclusion; 6. Experience of bowel surgery for RE-associated fistula.

Primary outcome measure(s)

  • The clinical response rate after treatment — 1 week, 4 weeks and 8 weeks
    Radiation Therapy Oncology Group (RTOG) scores

Trial sites (1)

FacilityCityRegionStatus
Department of Microbiota Medicine & Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07331688 on ClinicalTrials.gov ↗ ← All trials in China